Predictors of Prosthetic Valve Endocarditis following Transcatheter Aortic Valve Replacement: A Meta-Analysis
DOI:
https://doi.org/10.1532/hsf.3461Keywords:
Prosthetic valve endocarditis, Transcatheter aortic valve replacement, Meta-analysis, Risk factorAbstract
Background: Transcatheter aortic valve replacement (TAVR) has gained increasing acceptance for patients with aortic disease. A rare but fatal complication prosthetic valve endocarditis (PVE) could greatly influence the clinical outcomes of TAVR. This meta-analysis aims to pin down the predictors of PVE in TAVR patients.
Methods: We performed a systematic search for studies that reported the incidence and risk factors of PVE after TAVR. Data on studies, patients, baseline characteristics, and procedural characteristics were abstracted. Crude risk ratios (RRs) and 95% confidence intervals for each predictor were calculated by the use of random-effects models.
Heterogeneity assumption was assessed by an I2 test.
Results: We obtained data from 8 studies that included 68,805 TAVR patients, of whom 1,256 (1.83%) were diagnosed with PVE after TAVR. 280 patients died within the 30-days of PVE diagnosis and the pooled in-hospital mortality was 22.3%. The summary estimates indicated an increased risk of PVE after TAVR for males (RR 1.53, P = .0001); for patients with orotracheal intubation (RR 1.65, P = .01), new pacemaker implantation (RR 1.46, P = .003), and residual aortic regurgitation (≥2 grade) (RR 1.62, P = .05); while older age (RR 0.97, P = .0007) and implantation of a self-expandable valve (RR 0.74, P = .02) were associated with a lower risk of PVE after TAVR.
Conclusion: Clinical characteristics and peri-
procedure factors including age, male sex, valve type, orotracheal intubation, pacemaker implantation, and residual regurgitation were proven to be associated with the occurrence of PVE-TAVR. Clinicians should pay particular attention to PVE when treating TAVR patients with these predictors.
References
Abdel-Wahab M, Neumann FJ, Mehilli J, et al. 2015. 1-year outcomes after transcatheter aortic valve replacement with balloon-expandable versus self-expandable valves: Results from the choice randomized clinical trial. J Am Coll Cardiol 66:791-800.
Amat-Santos IJ, Messika-Zeitoun D, Eltchaninoff H, et al. 2015. Infective endocarditis after transcatheter aortic valve implantation: Results from a large multicenter registry. Circulation 131:1566-74.
Anantha-Narayanan M, Reddy YNV, Sundaram V, et al. 2020. Endocarditis risk with bioprosthetic and mechanical valves: Systematic review and meta-analysis. Heart 106:1413-19.
Athappan G, Patvardhan E, Tuzcu EM, et al. 2013. Incidence, predictors, and outcomes of aortic regurgitation after transcatheter aortic valve replacement: Meta-analysis and systematic review of literature. J Am Coll Cardiol 61:1585-95.
Bax JJ, Delgado V. 2019. Prosthetic valve endocarditis after surgical and transcatheter aortic valve replacement: Infrequent, but poor outcome. Euro Intervention 15:e484-5.
Ben-Shoshan J, Amit S, Finkelstein A. 2016. Transcatheter aortic valve implantation infective endocarditis: Current data and implications on prophylaxis and management. Curr Pharm Des 22:1959-64.
Bjursten H, Rasmussen M, Nozohoor S, et al. 2019. Infective endocarditis after transcatheter aortic valve implantation: A nationwide study. Eur Heart J 40:3263-9.
Braghiroli J, Kapoor K, Thielhelm TP, Ferreira T, Cohen MG. 2020. Transcatheter aortic valve replacement in low risk patients: A review of partner 3 and EVOLUT low risk trials. Cardiovasc Diagn Ther 10:59-71.
Butt JH, Ihlemann N, De Backer O, et al. 2019. Long-term risk of infective endocarditis after transcatheter aortic valve replacement. J Am Coll Cardiol 73:1646-55.
Fauchier L, Bisson A, Herbert J, et al. 2020. Incidence and outcomes of infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement. Clin Microbiol Infect 26:1368-74.
Glaser N, Jackson V, Holzmann MJ, Franco-Cereceda A, Sartipy U. 2017. Prosthetic valve endocarditis after surgical aortic valve replacement. Circulation 136:329-31.
Higgins JP, Thompson SG. 2002. Quantifying heterogeneity in a meta-analysis. Stat Med 21:1539-58.
Kolte D, Goldsweig A, Kennedy KF, et al. 2018. Comparison of incidence, predictors, and outcomes of early infective endocarditis after transcatheter aortic valve implantation versus surgical aortic valve replacement in the united states. Am J Cardiol 122:2112-9.
Kuttamperoor F, Yandrapalli S, Siddhamsetti S, Frishman WH, Tang GHL. 2019. Infectious endocarditis after transcatheter aortic valve replacement: Epidemiology and outcomes. Cardiol Rev 27:236-41.
Liberati A, Altman DG, Tetzlaff J, et al. 2009. The prisma statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: Explanation and elaboration. BMJ 339:b2700.
Mack MJ, Leon MB, Thourani VH, et al. 2019. Transcatheter aortic-valve replacement with a balloon-expandable valve in low-risk patients. N Engl J Med 380:1695-705.
Manne MB, Shrestha NK, Lytle BW, et al. 2012. Outcomes after surgical treatment of native and prosthetic valve infective endocarditis. Ann Thorac Surg 93:489-93.
Misawa Y. 2015. Valve-related complications after mechanical heart valve implantation. Surg Today 45:1205-9.
Olsen NT, De Backer O, Thyregod HG, et al. 2015. Prosthetic valve endocarditis after transcatheter aortic valve implantation. Circ Cardiovasc Interv 8:e001939.
Popma JJ, Deeb GM, Yakubov SJ, et al. 2019. Transcatheter aortic-valve replacement with a self-expanding valve in low-risk patients. N Engl J Med 380:1706-15.
Regev E, Finkelstein A, Assali A, et al. 2017. Comparison of outcome of transcatheter aortic valve implantation for severe aortic stenosis in 3 age groups (=70; 71 to 80, and >/=81 years). Am J Cardiol 120:1607-11.
Regueiro A, Linke A, Latib A, et al. 2016. Association between transcatheter aortic valve replacement and subsequent infective endocarditis and in-hospital death. JAMA 316:1083-92.
Regueiro A, Linke A, Latib A, et al. 2019. Infective endocarditis following transcatheter aortic valve replacement: Comparison of balloon- versus self-expandable valves. Circ Cardiovasc Interv 12:e007938.
Tabata N, Al-Kassou B, Sugiura A, et al. 2020. Predictive factors and long-term prognosis of transcatheter aortic valve implantation-associated endocarditis. Clin Res Cardiol 109:1165-76.
Tan HL, Chai LY, Yeo TC, Chia BL, Tambyah PA, Poh KK. 2015. Predictors of in-hospital adverse events in patients with prosthetic valve infective endocarditis. Heart Lung Circ 24:705-9.
Thyregod HG, Steinbruchel DA, Ihlemann N, et al. 2015. Transcatheter versus surgical aortic valve replacement in patients with severe aortic valve stenosis: 1-year results from the all-comers notion randomized clinical trial. J Am Coll Cardiol 65:2184-94.
Waksman R, Rogers T, Torguson R, et al. 2018. Transcatheter aortic valve replacement in low-risk patients with symptomatic severe aortic stenosis. J Am Coll Cardiol 72:2095-105.
Young Lee M, Chilakamarri Yeshwant S, Chava S, Lustgarten LD. 2015. Mechanisms of heart block after transcatheter aortic valve replacement - cardiac anatomy, clinical predictors and mechanical factors that contribute to permanent pacemaker implantation. Arrhythm Electrophysiol Rev 4:81-5.
Published
How to Cite
Issue
Section
Author Disclosure & Copyright Transfer Agreement
In order to publish the original work of another person(s), The Heart Surgery Forum® must receive an acknowledgment of the Author Agreement and Copyright Transfer Statement transferring to Forum Multimedia Publishing, L.L.C., a subsidiary of Carden Jennings Publishing Co., Ltd. the exclusive rights to print and distribute the author(s) work in all media forms. Failure to check Copyright Transfer agreement box below will delay publication of the manuscript.
A current form follows:
The author(s) hereby transfer(s), assign(s), or otherwise convey(s) all copyright ownership of the manuscript submitted to Forum Multimedia Publishing, LLC (Publisher). The copyright transfer covers the exclusive rights to reproduce and distribute the article and the material contained therein throughout the world in all languages and in all media of expression now known or later developed, including but not limited to reprints, photographic reproduction, microfilm, electronic data processing (including programming, storage, and transmission to other electronic data record(s), or any other reproductions of similar nature), and translations.
However, Publisher grants back to the author(s) the following:
- The right to make and distribute copies of all or part of this work for use of the author(s) in teaching;
- The right to use, after publication in The Heart Surgery Forum, all or part of the material from this work in a book by the author(s), or in a collection of work by the author(s);
- The royalty-free right to make copies of this work for internal distribution within the institution/company that employs the author(s) subject to the provisions below for a work-made-for-hire;
- The right to use figures and tables from this work, and up to 250 words of text, for any purpose;
- The right to make oral presentations of material from this work.
Publisher reserves the right to grant or refuse permission to third parties to republish all or part of the article or translations thereof. To republish, such third parties must obtain written permission from the Publisher. (This is in accordance with the Copyright Statute, United States Code, Title 17. Exception: If all authors were bona fide officers or employees of the U.S. Government at the time the paper was prepared, the work is a “work of the US Government” (prepared by an officer or employee of the US Government as part of official duties), and therefore is not subject to US copyright; such exception should be indicated on signature lines. If this work was prepared under US Government contract or grant, the US Government may reproduce, royalty-free, all or portions of this work and may authorize others to do so, for official US Government purposes only, if the US Government contract or grant so requires.
I have participated in the conception and design of this work and in the writing of the manuscript and take public responsibility for it. Neither this manuscript nor one with substantially similar content under my authorship has been published, has been submitted for publication elsewhere, or will be submitted for publication elsewhere while under consideration by The Heart Surgery Forum, except as described in an attachment. I have reviewed this manuscript (original version) and approve its submission. If I am listed above as corresponding author, I will provide all authors with information regarding this manuscript and will obtain their approval before submitting any revision. I attest to the validity, accuracy, and legitimacy of the content of the manuscript and understand that Publisher assumes no responsibility for the validity, accuracy, and legitimacy of its content. I warrant that this manuscript is original with me and that I have full power to make this Agreement. I warrant that it contains no matter that is libelous or otherwise unlawful or that invades individual privacy or infringes any copyright or other proprietary right. I agree to indemnify and hold Publisher harmless of and from any claim made against Publisher that relates to or arises out of the publication of the manuscript and agree that this indemnification shall include payment of all costs and expenses relating to the defense of any such claim, including all reasonable attorney’s fees.
I warrant that I have no financial interest in the drugs, devices, or procedures described in the manuscript (except as disclosed in the attached statement).
I state that the institutional Human Subjects Committee and/or the Ethics Committee approved the clinical protocol reported in this manuscript for the use of experimental techniques, drugs, or devices in human subjects and appropriate informed consent documents were utilized.
Furthermore, I state that any and all animals used for experimental purposes received humane care in USDA registered facilities in compliance with the “Principles of Laboratory Animal Care” formulated by the National Society for Medical Research and the “Guide for the Care and Use of Laboratory Animals” prepared by the Institute of Laboratory Animal Resources and published by the National Institutes of Health (NIH Publication No. 85-23, revised 1985).
